Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab + IMRT in Intermediate-risk Nasopharyngeal Carcinoma
NCT05229315Phase 2Unknown
- Start
- Mar 2022
- Primary completion
- Dec 2023
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of toripalimab in nasopharyngeal carcinoma (NPC). Status: unknown.
02
Drugs
toripalimab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT05229315.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05229315.